Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Γδ and Αβ T-Cell Large Granular Lymphocytic Leukemia Have Similar Characteristics and Outcomes

Blood (2024) 144 (Supplement 1): 1678.

https://doi.org/10.1182/blood-2024-202457

Published: 2024

Journal Articles

Determination of MYD88 and CXCR4 Mutation for Clinical Detection and Their Significance in Waldenström Macroglobulinemia

Blood (2024) 144 (Supplement 1): 4349.

https://doi.org/10.1182/blood-2024-202324

Published: 2024

Journal Articles

Response-Driven Dose-Intensified Immunochemotherapy ± Autologous Stem Cell Transplantation in Previously Untreated Patients with High-Risk Aggressive B-Cell Lymphoma: Results of the DLCL002 Phase 2 Trial

Ting Xie, Wei Liu, Wenyang Huang, Huimin Liu, Weiwei Sui, Yi Wang, Wenjie Xiong, Yan Xu, Lugui Qiu, Dehui Zou

Blood (2024) 144 (Supplement 1): 4481.

https://doi.org/10.1182/blood-2024-204363

Published: 2024

Journal Articles

Classification of NK-Large Granular Lymphocytic Leukemia By CD56 Expression

Blood (2024) 144 (Supplement 1): 4439.

https://doi.org/10.1182/blood-2024-201476

Published: 2024

Journal Articles

Promising Safety and Efficacy of Trovocabtagene Autoleucel (C-CAR088) Followed ASCT in Ultra High-Risk Multiple Myeloma (UHR-MM) Patients

Blood (2024) 144 (Supplement 1): 7236.

https://doi.org/10.1182/blood-2024-197883

Published: 2024

Journal Articles

Phase II Clinical Study of Zanubrutinib Combined with Bendamustine and Rituximab (ZBR) for Time-Limited Treatment of Waldenstrom Macroglobulinemia

Xiong Wenjie, Yuting Yan, Ying Yu, Tingyu Wang, Wei Liu, Gang An, Weiwei Sui, Wenyang Huang, Dehui Zou, Lu-Gui Qiu, Shuhua Yi

Blood (2024) 144 (Supplement 1): 6324.

https://doi.org/10.1182/blood-2024-198882

Published: 2024

Journal Articles

Zanubrutinib Plus Ixazomib & Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia:a Phase II Studyshort Title: Zid for Waldenström Macroglobulinemia

Xiong Wenjie, Yuting Yan, Tingyu Wang, Weiwei Sui, Ying Yu, Tengteng Yu, Rui Lyu, Wei Liu, Huimin Liu, Gang An, Wenyang Huang, Dehui Zou, Lu-Gui Qiu, Shuhua Yi

Blood (2024) 144 (Supplement 1): 1648.

https://doi.org/10.1182/blood-2024-198864

Published: 2024

Journal Articles

Mitoxantrone Hydrochloride Liposome, Gemcitabine, Vinorelbine with or without Rituximab (GVM±R) in Patients with Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

Wei Liu, Yi Wang, Yan Xu, Chenxing Du, Qi Wang, Tingyu Wang, Wenyang Huang, Shuaishuai Zhang, Shuhua Yi, Yuting Yan, Tengteng Yu, Weiwei Sui, Gang An, Rui Lyu, Huimin Liu, Wenjie Xiong, Mingwei Fu, Dehui Zou, Lugui Qiu

Blood (2023) 142 (Supplement 1): 6232.

https://doi.org/10.1182/blood-2023-185669

Published: 2023

Journal Articles

The Incidence, Clinical Application and Prognostic Significance of MYD88 and CXCR4 Mutation in Chinese Patients with Lymphoplasmacytic Lymphoma/ Waldenström Macroglobulinemia

Ying Yu, Yuting Yan, Jun Wang, Wenjie Xiong, Yao Yao, Yanshan Huang, Rui Lyu, Tingyu Wang, Qi Wang, Wei Liu, Gang An, Weiwei Sui, Yan Xu, Wenyang Huang, Dehui Zou, Zhijian Xiao, Lugui Qiu, Shuhua Yi

Blood (2023) 142 (Supplement 1): 6089.

https://doi.org/10.1182/blood-2023-188786

Published: 2023

Journal Articles

The Prognostic Impact of Measurable Residual Disease Dynamics in Mantle Cell Lymphoma

Yanshan Huang, Yuting Yan, Ying Yu, Li Yuxi, Rui Lv, Tingyu Wang, Wenjie Xiong, Qi Wang, Wei Liu, Gang An, Weiwei Sui, Yan Xu, Wenyang Huang, Dehui Zou, Lugui Qiu, Shuhua Yi

Blood (2023) 142 (Supplement 1): 3038.

https://doi.org/10.1182/blood-2023-188881

Published: 2023

Journal Articles

Classification of NK-Large Granular Lymphocytic Leukemia By CD56 Expression

Li Yuxi, Ying Yu, Yanshan Huang, Rui Cui, Jingwen Sun, Rui Lyu, Tingyu Wang, Wenjie Xiong, Yuting Yan, Qi Wang, Wei Liu, Gang An, Weiwei Sui, Yan Xu, Wenyang Huang, Dehui Zou, Lugui Qiu, Shuhua Yi

Blood (2023) 142 (Supplement 1): 1649.

https://doi.org/10.1182/blood-2023-186068

Published: 2023

Journal Articles

Promising Safety and Efficacy of Trovocabtagene Autoleucel (C-CAR088) Followed ASCT in Ultra High-Risk Multiple Myeloma (UHR-MM) Patients Who Failed or Had Suboptimal Response to Standard First Line Triplet Based Therapy

Blood (2023) 142 (Supplement 1): 6864.

https://doi.org/10.1182/blood-2023-184868

Published: 2023

Journal Articles

Static and Dynamic Assessment to Identify Ultra-High Risk Multiple Myeloma：Analysis for Patients with Overall Survival No More Than Three Years

Yan Xu, Gang An, Shuhui Deng, Weiwei Sui, Wei Liu, Wenyang Huang, Tingyu Wang, Shuhua Yi, Dehui Zou, Lugui Qiu

Blood (2023) 142 (Supplement 1): 6701.

https://doi.org/10.1182/blood-2023-189353

Published: 2023

Journal Articles

A Retrospective, Matched Paired Analysis Comparing GBM/GBC Versus BEAM/Beac Conditioning Regimen for Autologous Stem Cell Transplantation in Non-Hodgkin's Lymphoma

Huimin Liu, Hesong Zou, Wei Liu, Wenyang Huang, Shuhui Deng, Rui Lv, Weiwei Sui, Yan Xu, Shuhua Yi, Tingyu Wang, Mingwei Fu, Gang An, Yaozhong Zhao, Lugui Qiu, Dehui Zou

Blood (2022) 140 (Supplement 1): 10585–10586.

https://doi.org/10.1182/blood-2022-163258

Published: 2022

Journal Articles

Zanubrutinib Plus Ixazomib and Dexamethasone for Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Prospective, Phase II Study

Ying Yu, ShuHua Yi, Xiong Wenjie, Tingyu Wang, Yuting Yan, Wei Liu, Weiwei Sui, Gang An, Yan Xu, Huimin Liu, Wenyang Huang, Dehui Zou, Lugui Qiu

Blood (2022) 140 (Supplement 1): 3587–3588.

https://doi.org/10.1182/blood-2022-162338

Published: 2022

Journal Articles

Long-Term Activity of Combining CNCT19 with HDT/ASCT in Refractory Large B-Cell Lymphoma: Two-Year Follow-up of a Prospective Phase 1/2 Clinical Trial

Wei Liu, Hesong Zou, Yan Xu, Huimin Liu, Chenxing Du, Rui Lv, Wenyang Huang, Weiwei Sui, Shuhua Yi, Lulu Lv, Lugui Qiu, Jianxiang Wang, Dehui Zou

Blood (2022) 140 (Supplement 1): 7472–7473.

https://doi.org/10.1182/blood-2022-166451

Published: 2022

Journal Articles

CNCT19 CAR T-Cell Therapy in Relapsed or Refractory B-Cell Lymphoma: Long-Term Results of a Pilot Prospective Clinical Study

Wei Liu, Wenyang Huang, Rui Lv, Huimin Liu, Shuhua Yi, Hong Liu, Lulu Lv, Lugui Qiu, Jianxiang Wang, Dehui Zou

Blood (2022) 140 (Supplement 1): 4598–4599.

https://doi.org/10.1182/blood-2022-167104

Published: 2022

Journal Articles

R-DA-Edoch/R-DHAP Alteration Could Overcome High Risk Factors in Younger Mantle Cell Lymphoma

Shuhua Yi, Yi Wang, Yuting Yan, Jiawen Chen, Wei Liu, Tingyu Wang, Gang An, Weiwei Sui, Wenyang Huang, Xiong Wenjie, Huimin Liu, Qi Sun, Huijun Wang, Zhijian Xiao, Jianxiang Wang, Dehui Zou, Lugui Qiu

Blood (2022) 140 (Supplement 1): 6512–6513.

https://doi.org/10.1182/blood-2022-165237

Published: 2022

Journal Articles

A Simple Risk-Scoring Model for Estimating the Prognostic Impact of 1q Gain in Patients with Newly-Diagnosed Multiple Myeloma

Fengyan Jin, Peiyu Yang, Haimin Chen, Xinyue Liang, Weiling Xu, Shanshan Yu, Wenyang Huang, Xingchen Yi, Qiang Guo, Mengru Tian, Tingting Yue, Mengyao Li, Yingjie Zhang, Mengxue Zhang, Yurong Yan, Zhongli Hu, Shaji K Kumar, Fan Zhou, Yun Dai

Blood (2022) 140 (Supplement 1): 4360–4361.

https://doi.org/10.1182/blood-2022-168602

Published: 2022

Journal Articles

Purine Nucleoside Analogs Plus Rituximab Is an Effective Treatment Choice for Hairy Cell Leukemia-Variant: Results from a Single Center in China

Tingyu Wang, Yi Wang, Ru Li, Ying Yu, Jiawen Chen, Rui Lyu, Wenjie Xiong, Qi Wang, Wei Liu, Wenyang Huang, Weiwei Sui, Gang An, Yan Xu, Dehui Zou, Jianxiang Wang, Lugui Qiu, Shuhua Yi

Blood (2021) 138 (Supplement 1): 3547.

https://doi.org/10.1182/blood-2021-150141

Published: 2021

NARROW

Γδ and Αβ T-Cell Large Granular Lymphocytic Leukemia Have Similar Characteristics and Outcomes

Determination of MYD88 and CXCR4 Mutation for Clinical Detection and Their Significance in Waldenström Macroglobulinemia

Response-Driven Dose-Intensified Immunochemotherapy ± Autologous Stem Cell Transplantation in Previously Untreated Patients with High-Risk Aggressive B-Cell Lymphoma: Results of the DLCL002 Phase 2 Trial

Classification of NK-Large Granular Lymphocytic Leukemia By CD56 Expression

Promising Safety and Efficacy of Trovocabtagene Autoleucel (C-CAR088) Followed ASCT in Ultra High-Risk Multiple Myeloma (UHR-MM) Patients

Phase II Clinical Study of Zanubrutinib Combined with Bendamustine and Rituximab (ZBR) for Time-Limited Treatment of Waldenstrom Macroglobulinemia

Zanubrutinib Plus Ixazomib & Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia:a Phase II Studyshort Title: Zid for Waldenström Macroglobulinemia

Mitoxantrone Hydrochloride Liposome, Gemcitabine, Vinorelbine with or without Rituximab (GVM±R) in Patients with Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

The Incidence, Clinical Application and Prognostic Significance of MYD88 and CXCR4 Mutation in Chinese Patients with Lymphoplasmacytic Lymphoma/ Waldenström Macroglobulinemia

The Prognostic Impact of Measurable Residual Disease Dynamics in Mantle Cell Lymphoma

Classification of NK-Large Granular Lymphocytic Leukemia By CD56 Expression

Promising Safety and Efficacy of Trovocabtagene Autoleucel (C-CAR088) Followed ASCT in Ultra High-Risk Multiple Myeloma (UHR-MM) Patients Who Failed or Had Suboptimal Response to Standard First Line Triplet Based Therapy

Static and Dynamic Assessment to Identify Ultra-High Risk Multiple Myeloma：Analysis for Patients with Overall Survival No More Than Three Years

A Retrospective, Matched Paired Analysis Comparing GBM/GBC Versus BEAM/Beac Conditioning Regimen for Autologous Stem Cell Transplantation in Non-Hodgkin's Lymphoma

Zanubrutinib Plus Ixazomib and Dexamethasone for Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Prospective, Phase II Study

Long-Term Activity of Combining CNCT19 with HDT/ASCT in Refractory Large B-Cell Lymphoma: Two-Year Follow-up of a Prospective Phase 1/2 Clinical Trial

CNCT19 CAR T-Cell Therapy in Relapsed or Refractory B-Cell Lymphoma: Long-Term Results of a Pilot Prospective Clinical Study

R-DA-Edoch/R-DHAP Alteration Could Overcome High Risk Factors in Younger Mantle Cell Lymphoma

A Simple Risk-Scoring Model for Estimating the Prognostic Impact of 1q Gain in Patients with Newly-Diagnosed Multiple Myeloma

Purine Nucleoside Analogs Plus Rituximab Is an Effective Treatment Choice for Hairy Cell Leukemia-Variant: Results from a Single Center in China

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only